EUNew treatments and approvals
Once-monthly eplontersen injection approved in the EU for nerve damage in hereditary TTR amyloidosis
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The European Commission approved eplontersen for hereditary TTR amyloidosis. The drug is for adults whose nerve involvement is at an early stage. It is injected under the skin once a month. The main trial included 144 patients. The drug reduced the harmful protein by 80%. Nerve damage progressed more slowly than in the comparison group.
What does it mean for patients and families?
The comparison group was taken from another study. Treatment is started by a specialist. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
Avrupa İlaç Ajansı (EMA) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Hereditary transthyretin amyloidosis (ATTRv)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.